Showing 881-890 of 951 results for "".
- FDA Approves Ingrezza Sprinkle Formulation for Tardive Dyskinesia or Chorea Associated with Huntington Diseasehttps://practicalneurology.com/news/fda-approves-ingrezza-sprinkle-formulation-for-tardive-dyskinesia-or-chorea-associated-with-huntington-disease/2470463/The Food and Drug Administration (FDA) has approved a new sprinkle formulation of Ingrezza (valbenazine; Neurocrine Biosciences, San Diego, CA) for patients with tardive dyskinesia (TD) or chorea associated with Huntington disease (HD). The oral granule capsules (available in 40 mg, 60 mg, and 80
- Large-Scale Study in The Lancet Neurology Documents Demographic, Clinical, and Biomarker Features Associated with Posterior Cortical Atrophyhttps://practicalneurology.com/news/large-scale-study-in-the-lancet-neurology-documents-demographic-clinical-features-and-biomarkers-associated-with-posterior-cortical-atrophy/2470389/Findings from a large-scaled research study published in The Lancet Neurology, provide new insight into the demographic characteristics of posterior cortical atrophy (PCA), which is a rare syndrome associated with the underlying neuropathologic features of Alzheimer disease (AD). Accordi
- Long-Term Data from LILAC-2 Study of Daybue for Rett Syndrome Reportedhttps://practicalneurology.com/news/long-term-data-from-lilac-2-study-of-daybue-for-rett-syndrome-reported/2470362/People who used Daybue (trofinetide; Acadia Pharmaceuticals, San Diego, CA) on a long-term basis showed improvements in the core symptoms of Rett syndrome, according to results of the 104-week LILAC-2 (NCT04776746) open-label extension (OLE) study. The safety profile results found in this OLE stu
- Novel Therapies for Migraine Treatment Based on Updates in Migraine Pathophysiology Explored by Dr. Andrew Charles, UCLAhttps://practicalneurology.com/news/novel-therapies-for-migraine-treatment-based-on-updates-in-migraine-pathophysiology-explored-by-dr-andrew-charles-ucla/2470339/The 2023 Scottsdale Headache Symposium featured a presentation by Dr. Andrew Charles, “The Future of Headache Therapeutics,” in which he examined how advances in the understanding of migraine pathophysiology are leading to novel therapeutic possibilities for migraine treatment. His pr
- FDA Grants Fast Track Designation to Autologous Investigational Cell Therapy for Parkinson Diseasehttps://practicalneurology.com/news/fda-grants-fast-track-designation-to-autologous-investigational-cell-therapy-for-parkinson-disease/2470319/ANPD001 (Aspen Neuroscience, San Diego, CA), a personalized, autologous investigational cell therapy product, has been granted Fast Track designation by the Food and Drug Administration (FDA) for investigation as a potential treatment for Parkinson disease (PD). ANPD001 is intended to replace los
- FDA Updates Nuplazid Label to Clarify Medication’s Indicationhttps://practicalneurology.com/news/fda-updates-nuplazid-label-to-clarify-medications-indication/2470299/The Food and Drug Administration (FDA) has updated the label for Nuplazid (pimavanserin; Acadia Pharmaceuticals, San Diego, CA) with revisions to the boxed warning and clinical studies sections for this atypical antipsychotic. The changes are intended to clarify that Nuplazid is used to treat peo
- New Drug Application Accepted for Oral Granule Sprinkle Formulation of Ingrezzahttps://practicalneurology.com/news/new-drug-application-accepted-for-oral-granule-sprinkle-formulation-of-ingrezza/2470295/The Food and Drug Administration (FDA) accepted the new drug application (NDA) for Ingrezza (valbenazine; Neurocrine Biosciences, San Diego, CA) oral granules. This is a new sprinkle formulation of the once-daily capsule version of Ingrezza, which was approved previously to treat tardive dyskines
- Indirect Treatment Comparison Between Ingrezza and Austedo to Treat Chorea Associated with Huntington Diseasehttps://practicalneurology.com/news/indirect-treatment-comparison-between-ingrezza-and-autesto-to-treat-chorea-associated-with-huntington-disease/2470278/Ingrezza (valbenazine; Neurocrine Biosciences, San Diego, CA) may provide more benefit in early treatment of chorea symptoms associated with Huntington disease (HD) than Austedo (deutetrabenazine; Teva Pharmaceuticals, Tel Aviv, Israel), according to results of a study presented at the 2023 Inter
- Ingrezza Approved for the Treatment of Chorea Associated with Huntington Diseasehttps://practicalneurology.com/news/ingrezza-approved-for-the-treatment-of-chorea-associated-with-huntington-disease/2470271/Ingrezza (valbenazine; Neurocrine Biosciences, San Diego, CA) has received approval from the Food and Drug Administration (FDA) for the treatment of adults with chorea associated with Huntington disease (HD). The agent, del
- FDA Grants Orphan Drug Designation to Exon 44 Skipping AOC for Duchenne Muscular Dystrophyhttps://practicalneurology.com/news/fda-grants-orphan-drug-designation-to-exon-44-skipping-aoc-for-duchenne-muscular-dystrophy/2470270/AOC 1044 (Avidity Biosciences, San Diego, CA), an antibody oligonucleotide conjugate (AOC), was granted orphan drug designation by the Food and Drug Administration (FDA) for the treatment of patients with Duchenne muscular